Zobrazeno 1 - 10
of 41
pro vyhledávání: '"F. V. Moiseenko"'
Autor:
E. V. Levchenko, F. V. Moiseenko, S. V. Orlov, E. N. Imyanitov, A. E. Mikhnin, M. L. Gelfond, E. N. Slugin, S. M. Ergnyan, N. E. Levchenko, A. S. Zhabina, A. M. Ulitin, O. Yu. Mamontov, O. O. Lopushanskaya, E. V. Artemeva, A. I. Murtazin, V. I. Shabinskaya
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 1, Pp 5-14 (2023)
Objective. To assess the overall and disease-free survival rates in patients with EGFR-mutated lung adenocarcinoma, who underwent surgery after achieving the objective response to tyrosine kinase inhibitor (TKI) therapy.Material and Methods. The over
Externí odkaz:
https://doaj.org/article/7336c9ed20724b46b7c9eb818dc1a744
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 3-4, Pp 11-17 (2022)
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patient
Externí odkaz:
https://doaj.org/article/2d03f1018a45430f833cbda769ac5776
Autor:
A. S. Zhabina, A. I. Novikov, F. V. Moiseenko, N. M. Volkov, E. O. Stepanova, E. V. Artemeva, N. H. Abduloeva, V. M. Moiseenko
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 8, Iss 2, Pp 34-42 (2021)
Purpose of the study. There is the generalized analysis of administration of vinflunine in real clinical practice in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological).Materials and methods. This analysis
Externí odkaz:
https://doaj.org/article/02ac5742c0f54e10b12b140e137026f4
Autor:
M. Yu. Fedyanin, К M. Ehlsnukaeva, I. A. Demidova, D. L. Stroyakovskiy, Yu. A. Shelygin, А. S. Tsukanov, М. V. Panina, V. Р. Shubin, F. V. Moiseenko, E. Yu. Karpenko, L. V. Bolotina, A. V. Kudryavtseva, М. L. Filipenko, I. P. Oskorbin, L. Yu. Vladimirova, N. N. Timoshkina, О. I. Kit, А. М. Stroganova, S. L. Dranko, А. I. Senderovich, А. А. Tryakin, S. А. Tjulandin
Publikováno v:
Медицинский совет, Vol 0, Iss 4S, Pp 52-63 (2021)
Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying pr
Externí odkaz:
https://doaj.org/article/21aec854212c4d9b9c6cc69e2d4c8fab
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, M. A. Lyadova, V. N. Vorobyeva, V. V. Petkau, A. V. Fateeva, E. S. Kuzmina, O. Yu. Novikova, V. A. Chubenko, N. Kh. Abduloeva, A. A. Kudryavtsev, E. O. Ignatova, R. R. Shakirov, O. A. Pardabekova, L. V. Kindyalova, S. P. Pelikh, O. A. Gladkov, S. A. Tjulandin, A. A. Tryakin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 1, Pp 11-20 (2021)
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods. This re
Externí odkaz:
https://doaj.org/article/ab81d2b18b6d483387d0ba158a69a3b1
Autor:
N. M. Volkov, M. S. Lebedeva, V. V. Egorenkov, F. V. Moiseenko, N. Kh. Abduloeva, A. A. Bogdanov, I. N. Terterov, V. V. Chernobrivceva, N. E. Valeeva, E. B. Myasnikova, A. S. Navatskaya, V. M. Moiseyenko
Publikováno v:
Креативная хирургия и онкология, Vol 11, Iss 2, Pp 109-117 (2021)
Background. Clinical reports on the coronavirus disease 2019 (COVID-19) suggest its higher incidence and worse outcomes in cancer patients. Considering a rapid pace of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic,
Externí odkaz:
https://doaj.org/article/1e6757aaf89345fd890388fbd4834607
Autor:
V. V. Egorenkov, F. V. Moiseenko, N. M. Volkov, M. S. Molchanov, M. S. Ravkina, N. Kh. Abduloeva, A. V. Linets, V. R. Khairutdinov, A. M. Ibragimov, V. M. Moiseyenko
Publikováno v:
Креативная хирургия и онкология, Vol 11, Iss 2, Pp 138-143 (2021)
Aim. Assessment of the utility and advantage of videoendoscopic inguinal femoral lymphadenectomy (VE-LAD) over the standard open technique (OLAD) in patients with malignant skin melanoma and metastatic lesions of regional inguinal and/or femoral lymp
Externí odkaz:
https://doaj.org/article/964b56bc85de4a31b51aae9d1931e327
Autor:
V. V. Egorenkov, F. V. Moiseenko, N. M. Volkov, M. S. Molchanov, M. S. Ravkina, N. Kh. Abduloeva, A. V. Linets, V. R. Khairutdinov, M. S. Aksenov, V. M. Moiseyenko
Publikováno v:
Креативная хирургия и онкология, Vol 11, Iss 2, Pp 118-124 (2021)
Background. Malignant melanoma is steadily exaggerating over the recent decades. Nonetheless, improved systemic therapies have substantially increased life expectancy in patients with a locally advanced or disseminated disease. Higherincidence recurr
Externí odkaz:
https://doaj.org/article/e0af05a22058440fa518230070309cf4
Autor:
T. Yu. Semiglazova, E. V. Lubennikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, A. V. Avramenko, E. V. Artemeva, S. A. Borozdina, A. A. Vakhitova, N. M. Volkov, I. P. Ganshina, Sh. A. Dzhalilova, L. G. Zhukova, B. S. Kasparov, A. A. Kachmazov, V. V. Klimenko, A. i. Kornietskaya, A. A. Meshcheryakov, A. A. Paichadze, A. N. Poltoratsky, O. E. Ryabishina, M. L. Stepanova, E. N Imyanitov
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 143-146 (2020)
Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of
Externí odkaz:
https://doaj.org/article/4dfe72bac118488ca84b9c829b2faa84
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://doaj.org/article/7960a21c1a0a4a80b8f80fc55c3111e3